SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 3, 2000
CELLEGY PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
(Exact name of Registrant as specified in its charter)
California
------------------------------------------------------
(State or other jurisdiction of incorporation)
0-26372 82-0429727
---------------------------- --------------------------
(Commission (IRS Employer
File Number) Identification No.)
349 Oyster Point Boulevard, Suite 200
South San Francisco, CA 94080
----------------------------------------------------- --------------------------
(Address of principal executive offices) (Zip Code)
(650) 616-2200
--------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
ITEM 5: OTHER EVENTS.
Filed with this report as Exhibit 99.01 is a press release issued by
the Registrant on October 3, 2000, announcing:
o On October 3, 2000, Cellegy Pharmaceuticals, Inc. (the "Company")
announced the issuance of 1,500,000 shares of the Company's Common
Stock in a private placement transaction. Cellegy has agreed to
file a registration statement covering the resale of the shares
issued in the transaction.
ITEM 7: FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
99.01 Press Release issued by the Registrant on October 3, 2000.
2
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: October 5, 2000 CELLEGY PHARMACEUTICALS, INC.
By: /s/ K. MICHAEL FORREST
------------------------------------------
K. Michael Forrest
President and Chief Executive Officer
3
